A
Antares Therapeutics
Biotech & Life Sciences · Boston, United States · Founded 2025
Development of precision oncology therapies, utilizing acquired discovery capabilities and a validated pipeline for patient treatments MoreLess
Antares is a biopharmaceutical entity concentrated on pioneering precision medicine, with a primary emphasis on oncology. The firm's genesis lies in the March 2025 acquisition of Scorpion Therapeutics by Lilly, enabling Antares to leverage Scorpion's established discovery capabilities and validated therapeutic pipeline.
Guidance is provided by an executive team with prior experience at Scorpion Therapeutics. Dr. Adam Friedman, with a background as a physician, scientist, and notable experience in oncology, leads as Chief Executive Officer. Amanda Valentino serves as Chief People Officer, contributing over two decades of experience in life sciences talent, human resources, and M&A.
Antares's operational strategy involves pushing scientific boundaries to develop novel therapies. The company's stated mission is to shape the future of precision medicine and deliver treatments that can transform patient lives, particularly within the oncology space. The target market encompasses advanced cancer therapeutics. The business model, characteristic of therapeutics firms, centers on research and development of new drugs, followed by clinical validation and eventual commercialization. The acquisition of its predecessor's assets by Lilly underscores the perceived value of its scientific platform and pipeline.
Keywords: Oncology, Precision Medicine, Therapeutics, Biopharmaceutical, Drug Development, Cancer Treatment, R&D, Pipeline, Life Sciences, Executive Leadership
Company overview
Antares Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2025
- Headquarters
- Boston, United States
- Employees
- 103
- Open positions
- 5
- Dealroom signal
- 55.4
Valuation & funding
Antares Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2025 | $177M | $708M | Vida Ventures · Willett Advisors · Tenmile · Vinyanshu Ventures | ↗ |
| CORPORATE SPINOUTOther financing | Jan 2025 | $0 | — | Scorpion Therapeutics | ↗ |
Growth signals
Antares Therapeutics website traffic
Latest recorded traffic for Antares Therapeutics is 6.9K monthly website visits, up 213.6% over the last three months. Antares Therapeutics's team grew 3% over the past year.
Hiring
Open positions at Antares Therapeutics
Current openings linked to this company in Dealroom.
Comparisons
Antares Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Antares Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Antares Therapeutics has talent and traffic
team presence
In the news
Latest news about Antares Therapeutics
Recent press, funding announcements, and product moves mentioning Antares Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Antares Therapeutics
An AI-synthesized read of the highest-engagement posts about Antares Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Antares Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.